

Amendments to the Claims:

No amendments have been made to the claims. The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 (canceled)

13. (previously presented) A composition comprising:
a hybridoma cell culture producing monoclonal antibodies which bind specifically to cocaine and cocaethylene and have low or no cross reactivity with benzoyl ecgonine.

14. (previously presented) The hybridoma cell line according to Claim 13, wherein said cell line is produced from a host immunized with an immunogen comprising at least one cocaethylene hapten conjugated to an antigenic protein, wherein said cocaethylene hapten comprises N-methyl tropane substituted at the 2-position with a carboxyethyl group and at the 3-position with a benzoyloxy group, wherein the benzoyloxy group is substituted at the para position with an aliphatic linking group of from 1-6 atoms, and said linking group comprises carbon atoms and 0 to 2 heteroatoms, said heteroatoms consisting of oxygen and nitrogen, wherein said aliphatic linking group terminating in said antigenic protein.

15. (previously presented) The hybridoma cell line according to Claim 13, wherein said cell line is produced from a host immunized with an immunogen comprising at least one cocaethylene hapten conjugated to an antigenic protein, wherein said cocaethylene hapten comprises N-methyl tropane substituted at the 2-position by carboxyethyl or N-ethylcarboxamide and at the 3-position by benzoyloxy or benzamido, wherein bonded at the para position of said benzoyloxy or benzamido is a linking group or a carboxy group is attached to said linking group, wherein at least one of the substituents has an amido group, and wherein said bonding to the antigenic protein is through said carboxyl group.

16. (previously presented) A monoclonal antibody produced by a hybridoma cell according to any one of Claims 13 to 15
17. (previously presented) A hybridoma cell line produced by fusing spleen cells from a host immunized with an immunogen according to Claim 15 with immortalized host B cells, wherein said hybridoma cell line produces a monoclonal antibody which reacts with cocaine and cocaethylene and has low or no cross reactivity with benzoyl ecgonine.
18. (previously presented) The hybridoma cell line according to Claim 17, wherein said antigenic protein is bovine serum albumin.
19. (previously presented) The hybridoma cell line according to Claim 17, wherein said antigenic protein is keyhole limpet hemocyanin.
20. (previously presented) The hybridoma cell line according to Claim 17, wherein said antigenic protein is tetanus toxoid.
21. (previously presented) A monoclonal antibody produced by a hybridoma cell line according to any one of Claims 17-20.
22. (previously presented) A monoclonal antibody according to Claim 21, wherein said monoclonal antibody is classified IgG, or equivalent thereof.
23. (previously presented) A monoclonal antibody, which binds specifically to cocaine and cocaethylene and has low or no cross reactivity to benzoyl ecgonine.
24. (previously presented) A monoclonal antibody according to Claim 23, labeled with an agent capable of providing a detectable signal.

25. (previously presented) A monoclonal antibody according to Claim 23, wherein said monoclonal antibody has an affinity of at least 5×10^8 for cocaine and cocaethylene and a comparatively low affinity for benzoyl ecgonine, wherein said monoclonal antibody is classified as IgG, or equivalent thereof.

26. (previously presented) A composition comprising a monoclonal antibody according to Claim 23.

PATENT

ATTORNEY DOCKET NO. DASI.002.03US


CONCLUSION

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (831) 648-3090, ext 103.

Respectfully submitted,

Dated:

July 13, 2004



Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/mnb